Logo

American Heart Association

  2
  0


Final ID: Mo4169

Isolated Tricuspid Replacement versus Repair among Medicare Beneficiaries

Abstract Body (Do not enter title and authors here): Background: Evidence is limited regarding mid-term outcomes following isolated tricuspid operations for tricuspid regurgitation at the population level.
Objective: This study aimed to compare the mid-term outcomes following isolated tricuspid valve replacement versus repair using contemporary data.
Methods: We analyzed the national data on Medicare beneficiaries aged ≥65 who underwent isolated tricuspid valve replacement or repair between January 2016 and December 2020. The primary outcome was mid-term (up to 3 years) all-cause mortality. The secondary outcomes included mid-term major adverse cardiovascular events (MACE) and heart failure hospitalizations, as well as in-hospital permanent pacemaker implantation rates. MACE comprised all-cause mortality, heart failure hospitalization, stroke, and tricuspid reoperations. A propensity score-matching analysis was conducted to compare the two groups.
Results: A total of 1,693 patients were included (replacement= 655 patients, repair= 1,038 patients). In the matched cohort (597 patients in each group), the overall mortality and MACE were 40% and 47% at 3 years, respectively. Tricuspid valve replacement was associated with similar all-cause mortality in comparison to repair (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.95-1.39; P=0.15). Similarly, the rates of MACE and heart failure hospitalizations were similar (adjusted HR, 1.10; 95% CI, 0.93-1.32, P=0.27; subdistribution HR, 1.07, 95% CI, 0.75-1.54, P=0.69, respectively) between these two procedures. Patients undergoing replacement required permanent pacemaker implantations more frequently (25.4% vs. 12.4%; P<0.001).
Conclusions: Isolated surgical tricuspid valve replacement was associated with similar clinical outcomes compared to repair, except for permanent pacemaker implantation rates. The overall high mid-term mortality and morbidity with either treatment highlight the need for better options and further research to optimize the indication and timing of intervention.
  • Shimoda, Tomonari  ( University of Tsukuba Hospital , Tsukuba City, Ibaraki , Japan )
  • Kuno, Toshiki  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Tsugawa, Yusuke  ( David Geffen School of Medicine at UCLA , Los Angeles , California , United States )
  • Ueyama, Hiroki  ( Emory University School of Medicine , Atlanta , Georgia , United States )
  • Miyamoto, Yoshihisa  ( University of Tokyo , Tokyo , Tokyo , Japan )
  • Watanabe, Atsuyuki  ( Mount Sinai Morningside and West , New York , New York , United States )
  • Gotanda, Hiroshi  ( Cedars-Sinai Medical Center , Los Angeles , California , United States )
  • Elmariah, Sammy  ( Univ California, San Francisco , San Francisco , California , United States )
  • Yokoyama, Yujiro  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Fukuhara, Shinichi  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Kaneko, Tsuyoshi  ( Washington University in St. Louis , St. Louis , Missouri , United States )
  • Author Disclosures:
    Tomonari Shimoda: DO NOT have relevant financial relationships | Toshiki Kuno: DO NOT have relevant financial relationships | Yusuke Tsugawa: DO NOT have relevant financial relationships | Hiroki Ueyama: DO NOT have relevant financial relationships | Yoshihisa Miyamoto: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):DeSC Healthcare:Active (exists now) | Atsuyuki Watanabe: DO NOT have relevant financial relationships | Hiroshi Gotanda: DO NOT have relevant financial relationships | Sammy Elmariah: DO have relevant financial relationships ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) | Yujiro Yokoyama: DO NOT have relevant financial relationships | Shinichi Fukuhara: No Answer | Tsuyoshi Kaneko: DO have relevant financial relationships ; Advisor:Edwards Lifesciences:Active (exists now) ; Advisor:Johnson and Johnson:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Advisor:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advanced Approaches in Valvular Disease: From Biomechanics to Clinical Practice

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
Adult congenital heart disease (ACHD) as career? Examining encouraging and discouraging factors around the globe in the Global ACHD Survey.

Bravo-jaimes Katia, Elizari Maria Amalia, Valdez Ramos Miriam, Cupido Blanche, Zentner Dominica, Almasri Murad, Phillips Sabrina, Mcleod Christopher, Burchill Luke, Bullock-palmer Renee, Windram Jonathan, Srour Mhd Osama, Jenkins Petra, Luna-lopez Raquel, Tutarel Oktay, Kandavello Geetha, Guerrero Carlos, García Cruz Edgar, Ackerman Judith

Association between Secondary Mitral Regurgitation and Left Atrial Structural Abnormalities in Atrial Fibrillation

Kassar Ahmad, Chamoun Nadia, Chahine Yaacoub, Akoum Nazem

More abstracts from these authors:
Transcatheter versus Surgical Tricuspid Repair among Medicare Beneficiaries: One-Year Results

Shimoda Tomonari, Ueyama Hiroki, Miyamoto Yoshihisa, Watanabe Atsuyuki, Gotanda Hiroshi, Tsugawa Yusuke, Kuno Toshiki

Salvaging Success: Navigating Next Steps After Initial SAVR or TAVR Failure in Young Patients

Kaneko Tsuyoshi, Fukuhara Shinichi, Nguyen Tom

You have to be authorized to contact abstract author. Please, Login
Not Available